ELUT Key Statistics, Chart & Performance
The current stock price of ELUT is 0.7 USD. In the past month the price decreased by -27.87%. In the past year, price decreased by -84.23%.
ELUT Latest News, Press Relases and Analysis
ELUT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.85 | 398.39B | ||
| AMGN | AMGEN INC | 15.12 | 178.02B | ||
| GILD | GILEAD SCIENCES INC | 14.77 | 150.06B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.24 | 115.57B | ||
| REGN | REGENERON PHARMACEUTICALS | 16 | 75.70B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 894.54 | 60.27B | ||
| INSM | INSMED INC | N/A | 43.83B | ||
| NTRA | NATERA INC | N/A | 33.56B | ||
| BIIB | BIOGEN INC | 10.88 | 26.72B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.36 | 20.87B | ||
| INCY | INCYTE CORP | 16.06 | 20.24B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.20B |
Related stock screener links
About ELUT
Company Profile
Elutia, Inc. is a biotechnology company, which engages in the provision of biologic products to improve compatibility between medical devices and the patients who need them. The company is headquartered in Silver Spring, Maryland and currently employs 51 full-time employees. The company went IPO on 2020-10-08. Its portfolio of products spans the Women’s Health and Cardiovascular markets. In Women’s Health, it offers SimpliDerm, a novel biological matrix that leverages the inherent science of natural healing processes. SimpliDerm's design uses human-based hydrated acellular dermal matrix (ADM), which mitigates inflammation and enhances tissue incorporation. In Cardiovascular, it sells its specialized porcine small intestine submucosa for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population. The company is focused on advancing NXT-41x, a biomatrix that directly addresses the root causes of reconstruction infections following mastectomy. NXT-41x combines biologics and extended antibiotic release to provide protection while supporting tissue regeneration.
Company Info
ELUTIA INC
12510 Prosperity Drive, Suite 370
Silver Spring MARYLAND US
Employees: 51
Phone: 12402471143
ELUTIA INC / ELUT FAQ
Can you describe the business of ELUTIA INC?
Elutia, Inc. is a biotechnology company, which engages in the provision of biologic products to improve compatibility between medical devices and the patients who need them. The company is headquartered in Silver Spring, Maryland and currently employs 51 full-time employees. The company went IPO on 2020-10-08. Its portfolio of products spans the Women’s Health and Cardiovascular markets. In Women’s Health, it offers SimpliDerm, a novel biological matrix that leverages the inherent science of natural healing processes. SimpliDerm's design uses human-based hydrated acellular dermal matrix (ADM), which mitigates inflammation and enhances tissue incorporation. In Cardiovascular, it sells its specialized porcine small intestine submucosa for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population. The company is focused on advancing NXT-41x, a biomatrix that directly addresses the root causes of reconstruction infections following mastectomy. NXT-41x combines biologics and extended antibiotic release to provide protection while supporting tissue regeneration.
What is the current price of ELUT stock?
The current stock price of ELUT is 0.7 USD. The price increased by 1.45% in the last trading session.
Does ELUT stock pay dividends?
ELUT does not pay a dividend.
What is the ChartMill rating of ELUTIA INC stock?
ELUT has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the analyst forecast for ELUT stock?
8 analysts have analysed ELUT and the average price target is 3.57 USD. This implies a price increase of 410% is expected in the next year compared to the current price of 0.7.
What is the Price/Earnings (PE) ratio of ELUTIA INC (ELUT)?
ELUTIA INC (ELUT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.68).
ELUT Technical Analysis
ELUT Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ELUT. Both the profitability and financial health of ELUT have multiple concerns.
ELUT Financial Highlights
Over the last trailing twelve months ELUT reported a non-GAAP Earnings per Share(EPS) of -0.68. The EPS increased by 73.95% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -63.61% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ELUT Forecast & Estimates
8 analysts have analysed ELUT and the average price target is 3.57 USD. This implies a price increase of 410% is expected in the next year compared to the current price of 0.7.
For the next year, analysts expect an EPS growth of 74.19% and a revenue growth -1.81% for ELUT